Ro Front-End GLP-1 Interface

Ro is turning branded GLP-1 access into a software and workflow problem instead of a pharmacy inventory problem. The important shift is that patients can stay inside Ro while the hard parts, prescription routing, manufacturer pharmacy handoff, refill coordination, dose changes, labs, and follow up, happen behind the scenes across Novo and Lilly channels. That makes Ro the consumer front door even when it does not own the drug supply.1 2 3 4 5

• The NovoCare link matters because it gives Ro direct access to manufacturer supplied Wegovy at a flat $499 cash price across all dose strengths, after NovoCare launched on March 5, 2025. That removes the old retail pharmacy hunt where patients bounced between prescriber, coupon, and out of stock pharmacy.1 2
• Ro is building the same front door on Lilly’s side. LillyDirect launched in January 2024, Zepbound KwikPen became available through LillyDirect at self pay prices starting at $299, and Ro launched KwikPen on platform in April 2026. The pattern is consistent, Ro handles intake and care, Lilly handles fulfillment.3 4 5
• This is a different model from weight loss apps like Noom, which pair coaching with some branded access, and from compounded GLP-1 sellers whose economics depend on making or sourcing the drug themselves. Ro is closer to a neutral care router sitting on top of both major branded manufacturers.6 7 8

The next step is that every new branded obesity launch, injectable, oral, or longer acting, can plug into the same Ro workflow without retraining patients on a new care path. If that holds, Ro becomes less like a telehealth clinic selling visits and more like the default operating layer manufacturers use to reach cash pay obesity patients.4 8